ANDA 76699, held by UCB. Carbidopa; Levodopa.
As of Nov 21, 2026, ANDA 76699 (Parcopa), held by UCB, was first approved by FDA on Aug 27, 2004, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 2004 | Original application | Approved |
| Parcopa10MG;100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet, orally disintegrating;oral | Carbidopa; Levodopa | Discontinued |
| Parcopa25MG;100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet, orally disintegrating;oral | Carbidopa; Levodopa | Discontinued |
| Parcopa25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet, orally disintegrating;oral | Carbidopa; Levodopa | Discontinued |
| Dec 30, 2010 | Supplement 4Labeling | Approved | None posted |
| Aug 27, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters